• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    10x Genomics Reports Third Quarter 2024 Financial Results

    10/29/24 4:05:00 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $TXG alert in real time by email

    PLEASANTON, Calif., Oct. 29, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the third quarter ended September 30, 2024.

    10x Genomics Logo (PRNewsfoto/10x Genomics, Inc.)

    Recent Highlights

    • Revenue was $151.7 million for the third quarter, in line with the company's preliminary announcement, a 1% decrease over the corresponding period of 2023, primarily driven by lower instrument revenue, offset by stronger contributions from consumables.
    • Began shipping GEM-X Flex, setting a new standard for the cost per cell for researchers and enabling them to run millions of cells for less than one cent per cell. GEM-X Flex also delivers a number of improvements that are particularly valuable for clinical FFPE samples.
    • Launched GEM-X Universal Multiplex, enabling researchers to run more cost-effective single cell studies decreasing the cost per sample, even for small scale experiments.
    • Began shipping Chromium Xo, providing a budget-friendly instrument for routine, high-performance single cell analysis.

    "Our results this quarter fell short of our expectations given greater-than-anticipated disruption from the sales restructuring we implemented in the quarter and cautious customer spending. As these dynamics persist, especially under a difficult macro backdrop, our revenue growth this year will be lower than our previous expectations," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "Despite these challenges, I am confident that the steps we are taking will enable us to reach more customers, execute consistently across the portfolio and drive the broad democratization of our technologies to reach the full potential of the large opportunity ahead."

    Third Quarter 2024 Financial Results

    Revenue was $151.7 million for the third quarter of 2024, a 1% decrease from $153.6 million for the corresponding prior year period.

    Gross margin was 70% for the third quarter of 2024, as compared to 62% for the corresponding prior year period. The increase in gross margin was primarily due to change in product mix.

    Operating expenses were $147.9 million for the third quarter of 2024, a 22% decrease from $190.3 million for the corresponding prior year period. The decrease was primarily driven by a $41.4 million in-process research and development expense related to an agreement to acquire certain intangible and other assets in the prior year period.

    Operating loss was $41.5 million for the third quarter of 2024, as compared to $94.8 million for the corresponding prior year period. Operating loss includes $33.9 million of stock-based compensation for the third quarter of 2024, as compared to $40.2 million of stock-based compensation for the corresponding prior year period. Operating loss in the third quarter of 2023 included $41.4 million of in-process research and development expense.

    Net loss was $35.8 million for the third quarter of 2024, as compared to a net loss of $93.0 million for the corresponding prior year period.

    Cash and cash equivalents were $398.2 million as of September 30, 2024.

    2024 Financial Guidance

    10x Genomics is updating its outlook for the full year 2024. The company now expects revenue to be in the range of $595 million to $605 million versus a prior range of $640 million to $660 million. The updated range represents a 3% decrease from the full year 2023 revenue at the midpoint.

    Webcast and Conference Call Information

    10x Genomics will host a conference call to discuss the third quarter 2024 financial results, business developments and outlook after market close on Tuesday, October 29, 2024, 2024 at 1:30 PM Pacific Time / 4:30 PM Eastern Time. A webcast of the conference call can be accessed at http://investors.10xgenomics.com. The webcast will be archived and available for replay at least 45 days after the event.

    About 10x Genomics

    10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn or X (Twitter). 

    Forward Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements included in this press release, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "see," "estimate," "predict," "potential," "would," "likely," "seek" or "continue" or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics, Inc.'s organization and organizational restructuring, commercial execution, opportunities, specifications, costs and adoption of 10x Genomics, Inc.'s products and services, expected performance advantages and benefits of using 10x Genomics, Inc.'s products and services and 10x Genomics, Inc.'s financial performance and results of operations, including expectations regarding revenue and guidance. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management. Actual outcomes and results could differ materially from these statements due to a number of factors and such statements should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release. 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in 10x Genomics' expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. The material risks and uncertainties that could affect 10x Genomics, Inc.'s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's most recently-filed 10-K for the fiscal year ended December 31, 2023 and the company's 10-Q for the quarter ended March 31, 2024 to be filed with the Securities and Exchange Commission (SEC) and elsewhere in the documents 10x Genomics, Inc. files with the SEC from time to time.

    Disclosure Information

    10x Genomics uses filings with the Securities and Exchange Commission, its website (www.10xgenomics.com), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

    Contacts

    Investors: [email protected]

    Media: [email protected]

    10x Genomics, Inc.

    Condensed Consolidated Statements of Operations

    (Unaudited)

    (In thousands, except share and per share data)





    Three Months Ended

    September 30,



    Nine Months Ended

    September 30,



    2024



    2023



    2024



    2023

    Revenue (1)

    $         151,654



    $         153,644



    $         445,764



    $         434,748

    Cost of revenue (2)

    45,261



    58,115



    142,237



    141,217

    Gross profit

    106,393



    95,529



    303,527



    293,531

    Operating expenses:















    Research and development (2)

    66,174



    66,507



    197,730



    205,065

    In-process research and development

    —



    41,402



    —



    41,402

    Selling, general and administrative (2)

    81,704



    82,415



    250,517



    257,205

    Total operating expenses

    147,878



    190,324



    448,247



    503,672

    Loss from operations

    (41,485)



    (94,795)



    (144,720)



    (210,141)

    Other income (expense):















    Interest income

    4,971



    4,300



    14,422



    12,269

    Interest expense

    (2)



    (1)



    (4)



    (25)

    Other income (expense), net

    2,078



    (1,248)



    982



    (4,268)

    Total other income, net

    7,047



    3,051



    15,400



    7,976

    Loss before provision for income taxes

    (34,438)



    (91,744)



    (129,320)



    (202,165)

    Provision for income taxes

    1,315



    1,242



    4,279



    3,982

    Net loss

    $          (35,753)



    $          (92,986)



    $       (133,599)



    $       (206,147)

















    Net loss per share, basic and diluted

    $              (0.30)



    $              (0.79)



    $              (1.11)



    $              (1.77)

    Weighted-average shares of common stock used in

    computing net loss per share, basic and diluted

    120,733,030



    117,728,293



    120,067,168



    116,693,008





    (1)

    The following table represents revenue by source for the periods indicated (in thousands). Spatial products includes the Company's Visium and Xenium products:

     



    Three Months Ended

    September 30,



    Nine Months Ended

    September 30,



    2024



    2023



    2024



    2023

    Instruments















    Chromium

    $              7,641



    $           12,231



    $           24,283



    $           36,716

    Spatial

    11,415



    22,711



    44,078



    48,357

    Total instruments revenue

    19,056



    34,942



    68,361



    85,073

    Consumables















    Chromium

    96,536



    100,282



    274,571



    302,172

    Spatial

    29,668



    14,091



    85,330



    37,067

    Total consumables revenue

    126,204



    114,373



    359,901



    339,239

    Services

    6,394



    4,329



    17,502



    10,436

    Total revenue

    $         151,654



    $         153,644



    $         445,764



    $         434,748



    The following table presents revenue by geography based on the location of the customer for the periods indicated (in thousands):

     



    Three Months Ended

    September 30,



    Nine Months Ended

    September 30,



    2024



    2023



    2024



    2023

    Americas















    United States

    $           84,723



    $           96,094



    $         250,032



    $         260,769

    Americas (excluding United States)

    3,099



    2,917



    10,511



    8,581

    Total Americas

    87,822



    99,011



    260,543



    269,350

    Europe, Middle East and Africa

    37,851



    32,019



    109,934



    91,687

    Asia-Pacific















    China

    15,030



    12,431



    42,692



    39,217

    Asia-Pacific (excluding China)

    10,951



    10,183



    32,595



    34,494

    Total Asia-Pacific

    25,981



    22,614



    75,287



    73,711

    Total revenue

    $         151,654



    $         153,644



    $         445,764



    $         434,748





    (2)

    Includes stock-based compensation expense as follows:

     



    Three Months Ended

    September 30,



    Nine Months Ended

    September 30,

    (in thousands)

    2024



    2023



    2024



    2023

    Cost of revenue

    $              2,169



    $              1,844



    $              6,127



    $              5,140

    Research and development

    15,978



    17,856



    50,728



    55,196

    Selling, general and administrative

    15,763



    20,535



    51,354



    67,696

    Total stock-based compensation expense

    $           33,910



    $           40,235



    $         108,209



    $         128,032

     

    10x Genomics, Inc.

    Condensed Consolidated Balance Sheets

    (Unaudited)

    (In thousands)





    September 30,

    2024



    December 31,

    2023

    Assets







    Current assets:







    Cash and cash equivalents

    $         398,159



    $         359,284

    Marketable securities

    —



    29,411

    Accounts receivable, net

    83,525



    114,832

    Inventory

    94,050



    73,706

    Prepaid expenses and other current assets

    18,159



    18,789

    Total current assets

    593,893



    596,022

    Property and equipment, net

    258,759



    279,571

    Operating lease right-of-use assets

    59,579



    65,361

    Goodwill

    4,511



    4,511

    Intangible assets, net

    16,149



    16,616

    Other noncurrent assets

    4,903



    3,062

    Total assets

    $         937,794



    $         965,143

    Liabilities and stockholders' equity







    Current liabilities:







    Accounts payable

    $           26,210



    $           15,738

    Accrued compensation and related benefits

    30,080



    30,105

    Accrued expenses and other current liabilities

    37,770



    56,648

    Deferred revenue

    17,760



    13,150

    Operating lease liabilities

    9,415



    11,521

    Total current liabilities

    121,235



    127,162

    Operating lease liabilities, noncurrent

    76,461



    83,849

    Deferred revenue, noncurrent

    12,349



    8,814

    Other noncurrent liabilities

    4,945



    4,275

    Total liabilities

    214,990



    224,100

    Commitments and contingencies







    Stockholders' equity:







    Preferred stock

    —



    —

    Common stock

    2



    2

    Additional paid-in capital

    2,140,789



    2,025,890

    Accumulated deficit

    (1,418,019)



    (1,284,420)

    Accumulated other comprehensive income (loss)

    32



    (429)

    Total stockholders' equity

    722,804



    741,043

    Total liabilities and stockholders' equity

    $         937,794



    $         965,143

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/10x-genomics-reports-third-quarter-2024-financial-results-302290509.html

    SOURCE 10x Genomics, Inc.

    Get the next $TXG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TXG

    DatePrice TargetRatingAnalyst
    2/13/2025$25.00 → $12.00Outperform → Market Perform
    Leerink Partners
    9/3/2024$35.00Outperform
    Leerink Partners
    7/22/2024$24.00Hold → Buy
    Jefferies
    7/18/2024$40.00 → $20.00Overweight → Neutral
    JP Morgan
    7/10/2024$55.00 → $25.00Buy → Hold
    Deutsche Bank
    6/27/2024Outperform → Peer Perform
    Wolfe Research
    6/25/2024Buy → Neutral
    Guggenheim
    6/3/2024$24.00Hold
    Jefferies
    More analyst ratings

    $TXG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mateo Alan bought $445,572 worth of shares (40,000 units at $11.14), increasing direct ownership by 184% to 61,691 units (SEC Form 4)

      4 - 10x Genomics, Inc. (0001770787) (Issuer)

      2/25/25 5:22:04 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TXG
    Financials

    Live finance-specific insights

    See more
    • 10x Genomics Reports First Quarter 2025 Financial Results

      PLEASANTON, Calif., May 8, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31, 2025. Recent Updates Revenue was $154.9 million for the first quarter. Excluding $16.8 million related to a patent litigation settlement, revenue was $138.1 million, a 2% decrease from the corresponding period of 2024, primarily driven by a significant decrease in instrument revenue.Ended the first quarter with cash and cash equivalents and marketable securities of $426.9 million. As

      5/8/25 4:05:00 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • 10x Genomics to Report First Quarter 2025 Financial Results on May 8, 2025

      PLEASANTON, Calif., April 14, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced it will report financial results for the first quarter ended March 31, 2025 after market close on Thursday, May 8, 2025. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call.

      4/14/25 4:05:00 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • 10x Genomics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Outlook for 2025

      PLEASANTON, Calif., Feb. 12, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided outlook for 2025. Recent Updates Revenue was $165.0 million for the fourth quarter and $610.8 million for the full year of 2024, representing 10% and 1% decreases over the corresponding periods of 2023.In collaboration with the Chan Zuckerberg Initiative (CZI) and Ultima Genomics, launched the Billion Cells Project, an effort to generate an unpre

      2/12/25 4:05:00 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TXG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • 10x Genomics Reports First Quarter 2025 Financial Results

      PLEASANTON, Calif., May 8, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31, 2025. Recent Updates Revenue was $154.9 million for the first quarter. Excluding $16.8 million related to a patent litigation settlement, revenue was $138.1 million, a 2% decrease from the corresponding period of 2024, primarily driven by a significant decrease in instrument revenue.Ended the first quarter with cash and cash equivalents and marketable securities of $426.9 million. As

      5/8/25 4:05:00 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • 10x Genomics to Participate in the BofA Securities 2025 Healthcare Conference

      PLEASANTON, Calif., April 30, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate in a fireside chat at the BofA Securities 2025 Healthcare Conference on Tuesday, May 13, at 11:20 a.m. Pacific Time. Interested parties may access a live webcast of the fireside chat on the "Investors" section of the company's website at: https://investors.10xgenomics.com/. The webcast will be archived and available for replay for at least 30 days after the event. About 10x Genomics

      4/30/25 4:05:00 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • 10x Genomics to Report First Quarter 2025 Financial Results on May 8, 2025

      PLEASANTON, Calif., April 14, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced it will report financial results for the first quarter ended March 31, 2025 after market close on Thursday, May 8, 2025. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call.

      4/14/25 4:05:00 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TXG
    Leadership Updates

    Live Leadership Updates

    See more
    • 10x Genomics Announces Senior Leadership Changes

      PLEASANTON, Calif., Aug. 8, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced today several changes to its executive team. Mennah Moustafa has been named Chief Commercial Officer, effective August 1. In this role, Moustafa will be responsible for driving commercial strategy and execution and leading the company's sales, support and marketing functions.Justin McAnear, Chief Financial Officer, will resign from the company effective August 30, to join a private company.Adam Taich has been appointed Chief Financial Officer

      8/8/24 4:05:00 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Fanatics Announces Appointment of Lydia Jett and Jonathan Mildenhall to Board of Directors

      Jett and Mildenhall will bring transformative vision and wide-ranging expertise to the fast-growing digital sports platform Separately, Fanatics releases its first environmental, social and governance (ESG) report Fanatics, a leading global digital sports platform, today announced the appointment of preeminent fintech, e-commerce and marketing executives Lydia Jett and Jonathan Mildenhall to its board of directors. Jett, Managing Partner and Head of Global eCommerce and US Consumer Internet Sector Investments at SoftBank Investment Advisers (SBIA), and Mildenhall, co-founder and Executive Chairman of TwentyFirstCenturyBrand and former CMO of Airbnb, bring decades of experience advising an

      5/5/22 8:30:00 AM ET
      $CPNG
      $GH
      $OZON
      $TXG
      Catalog/Specialty Distribution
      Consumer Discretionary
      Medical Specialities
      Health Care
    • ReCode Therapeutics Appoints Shehnaaz Suliman, M.D., MBA, M.Phil., as Chief Executive Officer

      Dr. Suliman brings over 25 years of drug development, deal-making and company building expertise as ReCode continues advancing its pipeline of novel genetic medicines using its powerful selective organ targeting (SORT) LNP delivery platform ReCode Therapeutics (the "Company"), a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary LNP delivery platform, today announced the appointment of Shehnaaz Suliman, M.D., MBA, M.Phil., as chief executive officer and as a member of the board of directors effective today. Former CEO, David Lockhart, Ph.D., will transition to the role of chief scientific officer and will remain president and a member of the boar

      1/10/22 8:00:00 AM ET
      $RARE
      $TXG
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TXG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • 10x Genomics downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded 10x Genomics from Outperform to Market Perform and set a new price target of $12.00 from $25.00 previously

      2/13/25 7:11:34 AM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Leerink Partners initiated coverage on 10x Genomics with a new price target

      Leerink Partners initiated coverage of 10x Genomics with a rating of Outperform and set a new price target of $35.00

      9/3/24 8:15:17 AM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • 10x Genomics upgraded by Jefferies with a new price target

      Jefferies upgraded 10x Genomics from Hold to Buy and set a new price target of $24.00

      7/22/24 8:21:12 AM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TXG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Saxonov Serge was granted 171,428 shares, increasing direct ownership by 19% to 1,092,968 units (SEC Form 4)

      4 - 10x Genomics, Inc. (0001770787) (Issuer)

      3/19/25 5:35:44 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Officer Hindson Benjamin J. was granted 120,535 shares, increasing direct ownership by 36% to 455,859 units (SEC Form 4)

      4 - 10x Genomics, Inc. (0001770787) (Issuer)

      3/19/25 5:35:12 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Chief Financial Officer Taich Adam was granted 335,632 shares (SEC Form 4)

      4 - 10x Genomics, Inc. (0001770787) (Issuer)

      3/19/25 5:34:38 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TXG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by 10x Genomics Inc.

      SC 13G - 10x Genomics, Inc. (0001770787) (Subject)

      11/8/24 2:46:37 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by 10x Genomics Inc.

      SC 13G - 10x Genomics, Inc. (0001770787) (Subject)

      11/5/24 6:07:26 AM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13G/A filed by 10x Genomics Inc.

      SC 13G/A - 10x Genomics, Inc. (0001770787) (Subject)

      10/4/24 2:14:32 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TXG
    SEC Filings

    See more
    • 10x Genomics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities, Financial Statements and Exhibits

      8-K - 10x Genomics, Inc. (0001770787) (Filer)

      5/8/25 4:05:10 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SCHEDULE 13G/A filed by 10x Genomics Inc.

      SCHEDULE 13G/A - 10x Genomics, Inc. (0001770787) (Subject)

      5/7/25 10:55:48 AM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SCHEDULE 13G/A filed by 10x Genomics Inc.

      SCHEDULE 13G/A - 10x Genomics, Inc. (0001770787) (Subject)

      5/7/25 10:40:41 AM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials